November 1, 2017 This article can be republished with kind authorization from our friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, discussions and debates. The Daily Health Policy Report is released for Kaisernetwork.org, a free of charge support of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Table Kaiser and Company Family Foundation. All rights reserved.. AHIP and AMA release healthcare TV ads America’s Health Insurance Plans and the American Medical Association start new television ads on health care.The Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy research was initiated to evaluate standard-dose and low-dosage regimens of peginterferon alfa-2b, plus ribavirin, after it had been observed that both dosage levels yielded similar prices of sustained virologic response in the lack of ribavirin.10 A third treatment group, peginterferon alfa-2a plus ribavirin, was put into the analysis because it is the other approved regimen. The target was to evaluate the protection and efficacy of both regular regimens and the experimental low-dose peginterferon alfa-2b program.